Cancer Immunology, Immunotherapy

, Volume 55, Issue 7, pp 819–829

Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate

Authors

    • IDM Research Laboratory
  • Nadège Bercovici
    • IDM Research Laboratory
  • Rachel Taylor
    • IDM Research Laboratory
  • Pierre Vereecken
    • Erasme-Bordet Medical OncologyULB
  • Séverine Massicard
    • IDM Research Laboratory
  • Dominique Duriau
    • Erasme-Bordet Medical OncologyULB
  • Frédérique Vernel-Pauillac
    • IDM Research Laboratory
    • Institut Pasteur de Nouvelle Calédonie
  • Aurélie Boyer
    • IDM Research Laboratory
  • Véronique Baron-Bodo
    • IDM Research Laboratory
  • Eric Mallard
    • IDM Research Laboratory
  • Jacques Bartholeyns
    • IDM Research Laboratory
  • Béatrice Goxe
    • IDM Research Laboratory
  • Nathalie Latour
    • IDM Research Laboratory
  • Sophie Leroy
    • IDM Research Laboratory
  • Didier Prigent
    • IDM Research Laboratory
  • Philippe Martiat
    • Erasme-Bordet Medical OncologyULB
  • François Sales
    • Erasme-Bordet Medical OncologyULB
  • Marianne Laporte
    • Erasme-Bordet Medical OncologyULB
  • Catherine Bruyns
    • Erasme-Bordet Medical OncologyULB
  • Jean-Loup Romet-Lemonne
    • IDM Research Laboratory
  • Jean-Pierre Abastado
    • IDM Research Laboratory
    • Institut Cochin (Inserm U567/UMR 8104)
  • Frédéric Lehmann
    • Erasme-Bordet Medical OncologyULB
    • Clinical R & DGlaxoSmithKline Biologicals
  • Thierry Velu
    • Erasme-Bordet Medical OncologyULB
Original Article

DOI: 10.1007/s00262-005-0078-6

Cite this article as:
Salcedo, M., Bercovici, N., Taylor, R. et al. Cancer Immunol Immunother (2006) 55: 819. doi:10.1007/s00262-005-0078-6

Abstract

The aim of the present phase I/II study was to evaluate the safety, immune responses and clinical activity of a vaccine based on autologous dendritic cells (DC) loaded with an allogeneic tumor cell lysate in advanced melanoma patients. DC derived from monocytes were generated in serum-free medium containing GM-CSF and IL-13 according to Good Manufacturing Practices. Fifteen patients with metastatic melanoma (stage III or IV) received four subcutaneous, intradermal, and intranodal vaccinations of both DC loaded with tumor cell lysate and DC loaded with hepatitis B surface protein (HBs) and/or tetanus toxoid (TT). No grade 3 or 4 adverse events related to the vaccination were observed. Enhanced immunity to the allogeneic tumor cell lysate and to TAA-derived peptides were documented, as well as immune responses to HBs/TT antigens. Four out of nine patients who received the full treatment survived for more than 20 months. Two patients showed signs of clinical response and received 3 additional doses of vaccine: one patient showed regression of in-transit metastases leading to complete remission. Eighteen months later, the patient was still free of disease. The second patient experienced stabilization of lung metastases for approximately 10 months. Overall, our results show that vaccination with DC loaded with an allogeneic melanoma cell lysate was feasible in large-scale and well-tolerated in this group of advanced melanoma patients. Immune responses to tumor-related antigens documented in some treated patients support further investigations to optimize the vaccine formulation.

Keywords

Allogeneic melanoma lysateDendritic cellsImmunotherapyT-cell responsesHuman clinical trial

Copyright information

© Springer-Verlag 2005